BAYN Stock Overview
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 1/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €26.73 |
52 Week High | €53.50 |
52 Week Low | €25.80 |
Beta | 0.97 |
1 Month Change | 0% |
3 Month Change | -17.93% |
1 Year Change | -55.75% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -47.38% |
Recent News & Updates
Recent updates
Shareholder Returns
BAYN | BG Pharmaceuticals | BG Market | |
---|---|---|---|
7D | 0% | 2.5% | 0.6% |
1Y | -55.8% | 9.7% | 17.1% |
Return vs Industry: BAYN underperformed the BG Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: BAYN underperformed the BG Market which returned 17.2% over the past year.
Price Volatility
BAYN volatility | |
---|---|
BAYN Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 5.0% |
Market Average Movement | 3.7% |
10% most volatile stocks in BG Market | 8.2% |
10% least volatile stocks in BG Market | 2.4% |
Stable Share Price: BAYN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1863 | 96,931 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
BAYN fundamental statistics | |
---|---|
Market cap | €26.87b |
Earnings (TTM) | -€2.94b |
Revenue (TTM) | €47.64b |
0.6x
P/S Ratio-9.1x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BAYN income statement (TTM) | |
---|---|
Revenue | €47.64b |
Cost of Revenue | €19.75b |
Gross Profit | €27.89b |
Other Expenses | €30.83b |
Earnings | -€2.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
Earnings per share (EPS) | -2.99 |
Gross Margin | 58.55% |
Net Profit Margin | -6.17% |
Debt/Equity Ratio | 132.3% |
How did BAYN perform over the long term?
See historical performance and comparison